BLACKSBURG, Va.--(BUSINESS WIRE)--Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon’s currently marketed Glyocofect™ transfection platform and expands the company’s offering in an $800 million market that is steadily growing at 15% annually. As pharmaceutical companies, clinical research physicians and diagnostic companies struggle to find new treatment options, theranostics are viewed as essential in optimizing medications for individual and sub-groups of patients. Techulon plans to bring the reagent to market for the benefit of health-related research and drug development.
